Illumina, Inc. (ILMN) Earnings Call Transcript & Summary

October 30, 2025

NASDAQ US Health Care Life Sciences Tools and Services earnings 57 min

Earnings Call Speaker Segments

Brian Blanchett

executive
#1

Good day, everyone, and thanks for joining Illumina's earnings call for the second quarter of 2025. During today's session, we'll go over the financial results we published following the close of the market, and we'll share some commentary prior to taking your questions in the Q&A portion. You can find our earnings release in the Investor Relations area of illumina.com. With us today are Jacob Thaysen, our Chief Executive Officer, and Ankur Dhingra, our Chief Financial Officer. Jacob is going to share an update regarding Illumina's businesses, and after that Ankur will walk through the company's financials. Every financial figure discussed on this call pertains to core Illumina. If you'd like historical consolidated financials, please see our earnings release along with our SEC filings. Kindly keep in mind that every year-over-year revenue growth rate we mention during the prepared remarks is given on a constant currency basis, so the effect of foreign exchange fluctuations is excluded. We ask that you take a look at the GAAP reconciliation of our non-GAAP measures, which is included in today's release as well as the supplemental data posted on our website. This call is being recorded.

Conor McNamara

executive
#2

Okay, let's get started. On today's call, we're going to go over the financial results we published after the market closed, and we'll give our prepared comments before we open things up for questions. You can find our earnings release in the Investor Relations section of illumina.com. With us today are Jacob Thaysen, our Chief Executive Officer, and Ankur Dhingra, our Chief Financial Officer. Jacob is going to begin with an update on Illumina's business, and then Ankur will walk through the company's financials; during this call we'll be talking about certain non-GAAP financial measures, and you can find a reconciliation to GAAP in today's release as well as in the supplementary data posted on our website. Just so you know, unless we say otherwise or unless we're referring to our end markets, every year-over-year revenue growth rate we discuss in our prepared remarks is given on a constant currency basis, which excludes the effect of foreign exchange fluctuations. Also, whenever we mention China, we mean our Greater China region, which includes Taiwan and Hong Kong as well. This call is being recorded, and a replay will be made available in the Investor section of our website. We intend for all forward-looking statements made during today's call to be protected under the Private Securities Litigation Reform Act of 1995. For a better understanding of the risks and uncertainties that could cause actual results to differ, please refer to the documents Illumina files with the SEC, including our most recent Forms 10-Q and 10-K; with that, I'll hand the call over to Jacob.

Jacob Thaysen

executive
#3

I appreciate that, Conor, and good afternoon to all of you. During Q3, we posted yet another robust set of results, with revenue, non-GAAP operating margin, and diluted EPS each landing above the range we had guided to. Total revenue came in at $1.08 billion, and outside of China we got back to growth, rising roughly 2% from the prior-year period. Our non-GAAP operating margin reached 24.5%, while non-GAAP diluted EPS was $1.34 — both showing substantial expansion compared with a year ago and surpassing our guidance. These results capture the momentum we are generating as we move through the NovaSeq X transition, particularly within clinical markets, where sequencing consumables revenue climbed at a high single-digit rate versus the same quarter last year. With that kind of strength behind us, we are lifting our overall full-year 2025 outlook, while keeping a disciplined approach as we watch macro conditions and funding trends through the remainder of the year. Looking at our end markets, clinical keeps speeding up. Customers are bringing forward new assays that call for greater sequencing capacity and intensity, and NovaSeq X is turning out to be the perfect answer, providing more throughput while preserving the trusted accuracy and workflow of their installed NovaSeq 6,000 instruments. Rising sequencing volumes are more than compensating for transitional pricing effects, producing both sequential and year-over-year gains in consumables revenue. On the research side, demand showed signs of stabilizing, though many labs are still watching their budgets closely given regulatory and funding uncertainty. Our teams stay deeply engaged with customers to support the continuity of their work. We also took encouragement from how resilient our business proved in Greater China, where revenue exceeded our guidance notwithstanding continuing export restrictions. As a reminder, a portion of our business is handled by OEM partners who sell our instruments and consumables into particular customer segments. We have now secured approval to serve those partners by manufacturing select instruments locally within Greater China. Although this represents a measured step forward, we have not yet arrived at a long-term resolution regarding our operations in Greater China, and we continue talking with the relevant agencies. Now, shifting to our strategy: during Q3, we made meaningful headway on the three pillars supporting our long-term financial targets — growing our core sequencing business, scaling into multi-omics, and expanding our services, data, and software capabilities. Taken together, these pillars are moving the discussion away from cost per gigabyte and toward providing the highest quality biological insights at the lowest end-to-end cost. Beginning with our core sequencing business. In Q3, NovaSeq X had another strong quarter, with over 55 instruments placed, consistent with our target of 50 to 60 placements each quarter. Most significantly, we hit the milestones we established for our high-throughput transition to NovaSeq X. We aimed to reach roughly 75% of high-throughput gigabases shipped and 50% of high-throughput revenue on the X platform by year-end, and here in Q3 we surpassed both. Our results underscore the strength and elasticity of sequencing demand. NovaSeq X consumables revenue growth sped up even as conversion from NovaSeq 6,000 rose, showing that our transition strategy is delivering. On the clinical side, that's still our biggest growth engine. New assay clearances, favorable reimbursement choices, and rising appetite for tests that use more sequencing are all behind it, and those forces leave us positioned to keep expanding steadily. With pricing pressure letting up and the research and market picture settling down, we think these factors will return us to the long-term revenue growth targets we've set. On to pillar two, which is about scaling into multi-omics. After we announced the Somalogic acquisition in Q2 — still expected to close in 2026 — we rolled out Illumina Protein Prep during Q3. This proteomic assay, which we co-developed, applies NGS power to protein analysis via one straightforward, integrated workflow, giving labs of every size scale, precision, and accessibility. Illumina Protein Prep handles measurement of as many as 9,500 proteins for each sample, returns highly consistent results in roughly 2.5 days, needs minimal hands-on time, and costs less per insight. A key point: Illumina Protein Prep works together with Dragon and the Illumina Complete Multi-Omics software suite we'll be launching soon, stretching our capabilities end to end, from sample prep all the way to interpreting data. Past proteomics, at ASHG earlier this month we broadened the multi-omics portfolio by introducing our five-base solution — a combined library prep and software product that reads genetic variances and DNA methylation at the same time. Built on proprietary chemistry plus our new Dragon algorithm, five-base keeps variant and methylation information intact within one workflow, yielding accurate single-base resolution and cutting both complexity and cost. Now pillar three, growing what we offer in services, data, and software. Earlier this month we unveiled BioInsight, a newly formed business meant to speed up how genomic and multi-omics data get used in drug discovery and research. BioInsight consolidates our population sequencing programs, data partnerships, and software and AI capabilities into a single structure, forming a more strategic platform for working with governments, biopharma, and research institutions. By merging progress in sequencing, economics, and AI, BioInsight lets customers produce and interpret data on a larger scale, which positions Illumina to seize fresh opportunities in this rapidly expanding area. Over the near term, BioInsight will concentrate on large-scale data generation partnerships, with longer-term intentions to monetize data, software, and AI-enabled services further, layering on additional growth that backs our long-term financial targets. Taken together, these efforts demonstrate how we're carrying out our strategy, stretching Illumina's reach from sequencing into multi-omics and from generating data into biological insights. They represent an innovation roadmap that serves customers right now while preparing for whatever comes after. During the quarter and at ASHG, I spoke with numerous customers — some excited about our recent launches and forthcoming solutions such as Constellations with Clear. Those conversations are just one of many channels we use to collect customer feedback, and we keep folding those insights into our roadmap. Putting customers first and understanding them sits at the core of how we run things, and my own conversations extend that same discipline. We stay centered on their top priorities — making sequencing simpler, easier to reach, and cheaper — which lets us forge stronger partnerships and improve our solutions. So because of that, our customers are moving into additional applications that rely heavily on sequencing, which stretches how far our technology reaches and how much impact it has. While at ASHG, those discussions confirmed once more that we hold a leading position. That standing rests on complete solutions, on how good and how consistent our data is, and on reliability and service we've demonstrated, and it also brought out how much trust customers have in Illumina as a partner for the long haul. Hearing that made us even more certain about the road in front of us and about our capacity to keep that leadership going for many years ahead. Going forward, disciplined execution stays our focus, along with carrying forward the momentum we built from Q3. In the near term, clinical remains the main engine of revenue growth, since NovaSeq X volume outweighs the pricing pressure tied to conversions by more than enough. On top of that, we expect our research business to gradually get back to growing as those pricing pressures ease and end markets settle down. Taken together, these forces leave us in a strong spot heading into 2026, and they give us confidence that we can reach high single-digit revenue growth along with 20% non-GAAP operating margins by 2027, not counting Greater China; and now I'll hand things to Ankur, who will take you through our Q3 results and outlook, and after that we'll go to Q&A.

Ankur Dhingra

executive
#4

Thanks, Jacob, and good afternoon to all of you. I'll walk you through how our third quarter turned out financially, offer additional detail on revenue, expenses, earnings, and capital deployment, and then discuss what we expect ahead. Before diving into the specifics of the financials, let me share a big-picture take on how Q3 unfolded. During the quarter, business outside China went back to growing, which marks a key milestone on the path toward our long-term objectives; we also moved substantially forward on the NovaSeq X transition, since more than 75% of volume and over 50% of revenue has now shifted to X. High-throughput consumables posted solid growth within our clinical business, thanks to ongoing X expansion. Revenue came in above the high end of our guidance range, was approximately flat worldwide, and rose roughly 2% year-over-year ex-China. Non-GAAP operating margin widened 190 basis points to 24.5%, while non-GAAP diluted EPS reached $1.34, up $0.20 versus a year ago. Let me now take you through the specifics of our financial performance. Third-quarter revenue totaled $1.08 billion, approximately flat year-over-year on both a constant currency and reported basis, and above the high end of our guidance range. Revenue excluding China, which accounts for 95% of our revenue, rose approximately 2% year-over-year. Greater China revenue came to $52 million. Sequencing consumables revenue reached $747 million, approximately flat year-over-year and up about 3% excluding China, on both a reported and constant currency basis. High-throughput volumes keep climbing as customers in research and clinical settings capitalize on the NovaSeq X instruments. In clinical, momentum remains solid, with double-digit revenue growth outside of China, fueled by wider adoption of comprehensive genomic profiling and rising use of sequencing-intensive applications such as (MRD) testing; in research and applied, consumable sales fell high single digits outside of China, reflecting ongoing funding uncertainty and pricing dynamics connected to the X transition. To give investors clearer visibility into these dynamics, we've introduced new disclosures for revenue outside China, showing instruments and consumables revenue as well as consumables revenue growth by clinical and research segments. You can find this on Slide 10. The X transition advanced considerably in Q3. Approximately 78% of volumes and 51% of revenue in Q3 was sequenced on X. 91% of research volumes were sequenced on X. The clinical X transition has moved to roughly 64% of volumes in the quarter. Our customers are leveraging X's capabilities to add content to their assays, expand into new indications, and pursue whole genome-based approaches, as you may have observed with multiple product launches and approvals over the last few months across therapy selection, (MRD), and genetic disease indications. Now that we've hit this transition milestone, we thought it would be useful to illustrate the conversion patterns among our clinical customers; on Slide 12, we examine the 40 customers that have fully transitioned to X as of Q3, and we see how elasticity of demand played out. When it comes to this set of customers, in the first year price was offset by volume, and then in year two both revenue and volume sped up; we remain in close conversations with our clinical customers regarding how they are growing and their plans for moving from 6K to X. Those plans back up an expectation of ongoing revenue growth in 2026 and past that. To be specific, our business with the biggest customers is expected to outpace the company's overall average rate, at minimum across our strategic plan period. Combined with the variety of new assays reaching the market and these customer discussions, that gives us confidence clinical demand will stay strong as the X transition moves forward. Turning to sequencing activity, total sequencing GB output across our connected high and mid-throughput instruments rose by over 30% year-over-year, powered by solid clinical strength, though research customers showed more subdued growth. Now for sequencing instruments, revenue came to $107 million, rising roughly 3% year-over-year in Q3 and 6% ex-China on both a reported and constant currency basis, fueled by widespread uptake of the MiSeq i100 Plus in low-throughput. NovaSeq X placements were robust, exceeding 55 in Q3. Consistent with recent patterns, more than 50% of Xs placed during Q3 went to clinical customers; in Greater China, our instruments business fell about 54% because of restrictions on exporting instruments into China. Sequencing service and other revenue reached $147 million, declining approximately 3% year-over-year, which was under our expectations. That drop largely stemmed from the timing of certain strategic partnership revenues. Switching to the remainder of Illumina's P&L, non-GAAP gross margin was 69.2% for the third quarter. Tariffs hit gross margins by about 220 basis points year-over-year. Non-GAAP operating expenses totaled $484 million, down roughly 6%, or $33 million year-over-year, which reflects the results of multi-year cost reduction programs while prioritizing key growth investments. Non-GAAP operating margin came to 24.5% in Q3, expanding 190 basis points year-over-year. Non-GAAP operating profit increased approximately 9% year-over-year, reflecting greater operating leverage from the improved cost structure. Looking at results below the line, non-GAAP other expense, mostly made up of net interest expense, was $13 million, and the non-GAAP tax rate was 18.6%, a bit above expectations. We keep evaluating long-term tax structure optimization to balance U.S. R&D benefits with efficient credit utilization across jurisdictions. Our average diluted shares were about 154 million, roughly 3 million less than last quarter, driven by a higher level of share repurchases, net of dilution from employee equity awards. All told, non-GAAP earnings per diluted share of $1.34 grew 18% year-over-year and landed well above our guidance range. Turning to cash flow, balance sheet, and capital allocation items for the quarter, cash flow provided by operations was a robust $284 million. Capital expenditures were $31 million, and free cash flow was $253 million. During the third quarter, we bought back around 1.24 million Illumina shares, paying an average of $97.10 apiece, which came to $120 million in total. When the quarter closed, $684 million was still available under our repurchase authorization, and our plan is to keep buying back stock when opportunities arise. Also, in the prior quarter, we signed a definitive agreement with Standard BioTools covering the acquisition of Somalogic along with certain other specified assets. We're engaged with regulatory authorities to secure clearance, and our expectation remains that the transaction will be completed during the first half of 2026. The quarter finished with about $1.28 billion in cash, cash equivalents, and short-term investments, alongside gross leverage of roughly 1.6x gross debt to last 12 months EBITDA. Turning now to our guidance for the year 2025. You may have noticed in the press release that we are raising our guidance for 2025. Beginning with revenue, for the Greater China region we're lifting our revenue guidance by $20 million, bringing it to approximately $220 million for the year. For the rest of the world, we're projecting revenue growth between 0.5% and 1.5% on a constant currency basis, unchanged at midpoint. As a result, we now anticipate total Illumina constant currency revenues to decline in the range of -0.5% to -1.5%. On a reported basis, that equates to Illumina revenue in the range of $4.27 billion to $4.31 billion, up $20 million at the midpoint relative to last guidance.

Ankur Dhingra

executive
#5

Turning now to what we're assuming for products in the rest of the world, leaving China out of the picture: sequencing consumables growth is now projected to land somewhere between 2.5% and 3%, which sits at the upper portion of the 1% to 3% range we gave previously. That bump comes from a solid Q3, fueled by greater sequencing consumables volumes among our clinical customers. On sequencing instruments, our guidance stays where it was — a decline of -6.5% to -4%. What balances that out involves services tied to the timing of revenue from certain strategic partnerships. Further down the P&L, given how well we executed and the results we delivered, plus a higher revenue outlook from China, we're lifting our non-GAAP operating margin target by roughly 60 basis points at the midpoint, putting the range at 22.75% to 23%. For full year 2025, the non-GAAP tax rate is now anticipated at about 20.5%, and weighted average shares outstanding for full year 2025 should come in around 156 million, capturing our Q3 repurchases. Tying this all together, non-GAAP diluted EPS guidance moves up by $0.20 at the midpoint, giving a range of $4.65 to $4.75, which works out to 13% growth year-over-year at the midpoint. Implicit in that guidance: for Q4 2025, year-over-year revenue growth in the rest of the world ex-China should climb to 4%, while China adds $33 million during Q4. As 2025 wraps up, we feel quite upbeat about the momentum generated by the successful NovaSeq X transition and the ongoing strength of our clinical business, along with the strides we've taken getting ready for multi-omics launches spanning single cell, spatial, and proteomics. Peering into 2026, three key trends stand out. First, on the clinical side, we foresee dynamics much like this year: robust volume growth and a continuing shift to X. Second, in research and applied, we expect conditions to stay muted, in line with the latter half of 2025, with pricing headwinds letting up now that 91% of high-throughput volume has moved to X. Third, our planned 2026 multi-omics launches will start adding to growth whenever research and markets bounce back. On the whole, we expect end markets in 2026 to resemble the second half of 2025. Detailed 2026 guidance will come when we report Q4 results; to wrap up, I want to express my sincere thanks once more to the Illumina team for their continued focus and disciplined execution all year long. This quarter was extremely encouraging, as we returned to growth and made significant progress toward our short and long-term goals. Thank you for joining our call tod ay. I'll now invite the operator to open the line for Q&A.

Puneet Souda

analyst
#6

Yeah, hey everyone. Appreciate the question. If it's okay, I'll combine my questions into a single one. Thanks for the specifics regarding that $33 million figure for China you're suggesting relative to the entire year. I'm simply attempting to figure out how we ought to consider China and, you know, 2026? It appears you're separating out China as you proceed. Perhaps you could give some detail on that. A larger issue is what has been competitively announced at ASHG? Does that result in any freezing on the research side and the applied side of the market? I'm grateful you're giving additional color on the clinical side. The final piece, if I may, clinical growth, 12%. Thanks for that. What should we anticipate for that across the full year and 2026, if you would? Thank you so much.

Jacob Thaysen

executive
#7

Hi Puneet, Jacob here. Thanks for that single question, which I believe contained a few smaller parts. Let me begin with the China setup. Above all, I'm extremely pleased with how China has performed. As you're aware, we still haven't resolved the situation in China, but we took a good step forward here by now being able to serve our OEM partners so they can serve their customers in China with instruments. I'm genuinely pleased about that. I'm also very happy to see how Jenny, our General Manager in China, and the Illumina team keep serving our customer in a challenging environment; they demonstrate real resilience in this. Of course, what we're also seeing, and we remain very pleasantly surprised about, is how. How much our customers truly do want to keep working with Illumina. They keep seeing the high quality and innovations, and they want to see us stay in the market; we are taking this right now quarter by quarter. It would be too early for us to go in and give you a view on 2026. Clearly, again, we need to find a way to resolve the situation, and we keep working with the regulators in China to find a solution for that.

Doug Schenkel

analyst
#8

Hi there, good afternoon, everyone. I have a couple of items. First, when I consider 2026, and taking into account the way you framed the trends during your prepared remarks, three points stand out strongly to me. Number one, it looks plausible that research revenue might be flat to down low singles in the coming year, assuming a fairly stable funding backdrop, given where things stand with the transition to the X. Number two, clinical revenue ought to increase, though perhaps in the mid-single digit to high single digit range, as volumes rise and customers keep moving over to the X — bearing in mind that slide you showed about the three-year precedent with clinical customers. Number three, China might represent a 50 basis point to 100 basis point drag on growth. When I combine those three items, mathematically, I arrive at low single-digit revenue growth, at least as a jumping-off point for the next year. I'm simply curious whether that's a sensible framework. The second item is that, operationally, you've somehow expanded margin by roughly 50 basis points year to date during a stretch when total revenue is down a couple of points, and that includes an almost 25% year-over-year drop in high-margin China revenue. That has been truly impressive. I'm just wondering what this implies for the margin outlook, or the margin outlook, as the environment returns to normal. Because on one side, you could make the case that you've already pulled forward plenty of operating levers to reach these levels. On the other side, the reality that you've sped up operating efforts the way you have might produce fairly material flow-through once revenue begins to climb again. I'd just encourage — it would be great simply to hear how you're thinking about this. Thank you.

Jacob Thaysen

executive
#9

Okay, Doug, I appreciate those questions. Let me take another run at 2026. Like I mentioned earlier, providing guidance isn't something we're going to do. Our view is that it makes a lot of sense to hold off until we've got a clearer picture of what's going to unfold across the coming quarter, how the market shifts, and naturally the regulatory landscape from a China standpoint as well. With that said, the framework you've laid out — treating clinical as the growth engine next year too, while research looks softer — that seems right to me. In our view, it feels more like a second-half type of situation. The way things look today, it's steadying but remains weak. Some lift should come from our recent launches in the multi-omics lineup. As we're thinking about it at this moment, China isn't something I'd factor into our framework right now. It's premature to tell where things stand there, where China is headed. Broadly speaking, regarding how we run this company and how tightly the team has stuck to execution, I'm optimistic about our chance to push margins even higher. And I feel quite confident about — as I noted in my prepared remarks — progressing toward that 26% target in 2027 and beyond.

Ankur Dhingra

executive
#10

Regarding profitability, Doug, that's a fair question. We're quite happy with how things went, particularly since part of what we're seeing this quarter stems from steps we've already put in place. The 190 basis point improvement in operating margin for the quarter is something I feel good about; we've implemented numerous cost-structure measures. As we look ahead, a number of initiatives have not yet delivered their complete impact on our P&L, particularly within gross margins, where our efforts continue around refining our manufacturing footprint. When it comes to OpEx, we believe we've made many structural moves. Certain ones still need time to fully materialize, yet simultaneously, we're also investing in growth. Moving forward, I expect further margin gains to come from cost initiatives, and just as certainly, from considerably stronger operating leverage considering our current position on cost structure.

Vijay Kumar

analyst
#11

Hi everyone, I appreciate you taking my question. Nice work on a strong sprint year — congratulations. I have two quick items, Jacob, and a follow-up for both of you. Regarding consumables, my understanding was that expectations for the quarter sat around $720, maybe $725-ish, considering the headwinds in China. I realize China performed better than expected. Did any pull forward occur within the academic and government segments? How do you, you know, when you examine that 3% consumables growth rate, how much is macro versus this transition impact? Could you break that down? And Ankur, for you: previously I believe you mentioned 500 basis points of margin expansion. Does that figure still hold, starting from current levels, considering how you've delivered on margins? Thanks.

Jacob Thaysen

executive
#12

Vijay, I appreciate the question. Absolutely, we're thrilled about Q3; consumables, in our view, were clearly a standout this quarter. Momentum also keeps building. What you're observing is simply how the quarter unfolded. No pull forward has occurred, neither from China nor from what we've observed at NIH. It's very encouraging that grants are beginning to flow once more, yet no catch-up effect emerged from spending by NIH customers, so to speak, or by grant recipients. That isn't something we're seeing right now. Naturally, we hold hope that more will come. Stabilizing this further, I believe, will require time.

Ankur Dhingra

executive
#13

One more point I'd make: most of the total results, with the remainder of the world, originated on the clinical side in that case, on the consumables side. Demand there is really strong. Regarding margin improvement, that 500 basis points represented the target we'd established for ourselves at the time of last year's analyst day, beginning from a level where our base sat much nearer to roughly 21%. In the aggregate, we're moving toward reaching those 500 basis points eventually. As I've mentioned, given how this business stands at approximately 69%, 70% gross margin, we certainly do see a long-term opportunity in that area, but we'll discuss it after we hit our initial milestone and proceed from that point.

Tycho Peterson

analyst
#14

Hello, and thank you. I have a few brief items. Given your remarks that research spending will be reduced in the coming year, what is your approach regarding grants that span multiple years? Conversely, what about letting laboratories draw on indirect funding for capital equipment, plus demand that has built up? That covers my first item. I realize you'd prefer not to discuss 2026 at length, but do you believe earnings can increase, considering the difficulties in China and with Roche? Perhaps this is for Ankur: regarding consumables this quarter, what portion of the beat came from China and from tariff-related charges? You didn't actually clarify the gross margin situation, which declined 130 basis points compared with a year earlier. Could you address that? Did pricing account for all of it? What actions are you taking to counteract it? You mentioned that some gross margin actions are in progress.

Jacob Thaysen

executive
#15

Regarding the initial inquiry about the research sector in 2026: I believe there remain, as you're aware, numerous complexities involved with both single-year and multi-year grants. At present, what we observe is that although awards have been issued, we haven't yet witnessed a significant number of researchers actually disbursing those funds. When you consider academic investigators today, typically they may receive multiple grants over the course of a year; it isn't a solitary grant that solely determines their choices, but rather the reliability of continued grant availability. That essentially captures what we, and what the academic marketplace, are still anticipating — the emergence of fresh predictability. Should they count on grants continuing to arrive throughout 2026? There exists some degree of that ambiguity that needs to resolve itself before conditions begin to appear more typical. We will certainly be prepared to act. In fact, I'm rather encouraged by our multi-omics offerings, which will prove highly pertinent for these kinds of customers once funding resumes. We hold strong conviction and believe we can expand our earnings in 2026 as well. I think we demonstrated that during 2025. There were numerous challenges originating from various directions. You can clearly observe that we managed to achieve it. Consequently, my assurance about our capabilities in 2026 is extremely elevated.

Ankur Dhingra

executive
#16

Allow me to take on the remaining two items. Regarding gross margin, which declined 130 basis points, tariffs account for nearly 220 basis points, and we'll get into that. We're trying to offset a portion of those. As a result, the rest of base gross margin rose roughly 90 basis points. The base business keeps performing really strongly. Over time, we're seeking a means to lessen the effect stemming from tariffs. On your question about the consumables beat, it was about evenly split between China and elsewhere, with the majority of the non-China portion in clinical. The surcharge landed precisely as we had guided; it arrived right on the forecast.

Dan Leonard

analyst
#17

Sorry about that. I have one question regarding the increase in clinical consumables; that double-digit growth figure, was there any favorable lumpiness included in it, or do you consider it more of a run rate?

Jacob Thaysen

executive
#18

Hi Dan, I appreciate the question; once more we're quite happy with how Q3 went and certainly with the clinical results. As you noticed both in the prepared remarks and on the slide, we saw a significant shift where high-throughput on the X went from 44% of revenue to 51%, while simultaneously moving a great deal of volume. It truly demonstrates that even amid this shift and transition, we're able to grow despite a rapid transition. That's what you're observing. There is no particular lumpiness here. I wouldn't assume this will be the run rate going forward, yet I do think we'll keep experiencing robust growth within the clinical space.

Patrick Donnelly

analyst
#19

Hi everyone, thanks for taking our questions. First off, I'm aware Roche has come up a few times. I'd really like to hear your take on how the competitive landscape looks. Jacob and Ankur, I know both of you were at ASHG, speaking with plenty of customers and checking out the product. Could you share your view on the competition, how that factor shapes 2026, and simply how you're weighing any pressure or freezing that might bring to the market, especially on the clinical side? Thanks so much, guys.

Jacob Thaysen

executive
#20

Yes, Patrick, I appreciate the question. Like I've said previously, competition has always existed for us in this area. There's certainly plenty of competition at present, and I'm glad about it. In my view, competition benefits us, our thinking, the way we challenge ourselves, and consequently how we turn into a stronger partner for our customers. Another thing I notice is that nearly all of our rivals attempt to compete and stand apart along just one axis. In truth, as you pointed out too, we've been talking with numerous customers, and they're far too savvy to focus on a single axis. Instead, they consider multiple axes: top-tier data quality paired with the finest workflow and the least end-to-end cost. The way I see it, and I believe our customers agree, is that Illumina alone truly delivers across every one of those axes while also continuing to innovate. I feel quite confident about our position and the competitive picture.

Mason Carrico

analyst
#21

Hi there, appreciate you giving me the chance to ask. If market conditions stay roughly the same through next year, how long can we count on that 50 to 60 X's each quarter holding up? What's the pipeline looking like right now? And say we end up with an NIH budget that's about flat — do you figure X placements would stay steady at roughly those levels?

Jacob Thaysen

executive
#22

Yes, Mason, I appreciate that. When this year began, we came out with guidance pointing to 50, 60 placements every quarter. You'll recall that in 2025, after we gave that guidance, what unfolded was, naturally, the difficult circumstances we faced in Greater China. On top of that came the hurdles with NIH and funding, and even so, we've managed to hit that algorithm. My expectation as well is that Q4 will come in above the year's average, which tends to be the case. Our instrument placements are always stronger in Q4. From what I can tell, there's no reason I can see that this pattern wouldn't carry forward into next year, though right now it's simply too soon to hand you anything concrete about precisely how we're viewing that range. Yes.

Ankur Dhingra

executive
#23

Mason, when we think about end markets, and you consider demand for sequencing overall, there are still plenty of applications that lean heavily on sequencing—both within clinical work and in research—that are gaining ground and keep gaining ground; we anticipate the sequencing ecosystem will keep expanding for several more years, and that really ought to turn into additional X placements too.

Kathleen Schultze

analyst
#24

Hi everyone, I appreciate the inquiry. It seems that within research and applied, the shift to NovaSeq X is essentially finished. I'm just wondering, how has the gigabyte output appeared among those customers during this year, as we attempt to gauge underlying activity levels? And on a related note, have you incorporated any effect from the government shutdown into your fourth quarter assumptions?

Jacob Thaysen

executive
#25

Okay, Katherine, I'll begin with the first item, which is examining the shift here, and we're extremely happy, though it also came as anticipated, that NovaSeq X would move over far more quickly in the research and academic setting. As you probably are aware, the situation there is that once a researcher wraps up their project on the 6K, whenever they receive a new project, they're able to begin right away on the X and tackle a larger single-cell project or anything else they happen to be doing within that specific research setting. That's quite unlike the clinical arena, where you must validate and you must confirm it functions on the new platform prior to us switching over. We're quite accustomed to this, and we anticipated that research applied would shift far more quickly. Now that the transition is complete, we observe that the pricing headwind is, naturally, diminishing. We are, naturally, optimistic regarding the future. Having said that, there remain, naturally, worries regarding NIH funding, and those will be quiet for now. Perhaps, Ankur, you could elaborate a bit more on this.

Ankur Dhingra

executive
#26

Katherine, when it comes to the real growth in GB volume, you've likely already put together from looking at our research revenue growth and consumables that GBs increased in both clinical and research this quarter. Clinical was far and away the stronger of the two. Research's growth rate has declined compared with what those rates have traditionally been, though it continues to expand. What we've seen in the broader funding climate is that demand and activity in that area have turned muted, yet GB still went up, just not at the 30% level we've mentioned.

Kyle Mikson

analyst
#27

Hi everyone, thanks for asking those. Nice work on the results and everything you've rolled out. It's a genuinely solid cloud picture here.

Jacob Thaysen

executive
#28

Thanks, Kyle.

Kyle Mikson

analyst
#29

Ankur, turning to you about R&D costs for the quarter — they fell quite a bit from one quarter to the next. That's roughly the smallest figure, dropping under $230 million for the first time since 2021. I'm curious whether that's the new baseline or whether it will rise from here, and how much of it ties to the recent or the upcoming product launches, plus your work to stay competitive, clearly, as well. Then just one fast question about the clinical side. That seems to be picking up speed. What exactly is fueling that? Are there additional catalysts that might open up more growth? Thanks.

Jacob Thaysen

executive
#30

Yeah, Kyle, let me take that, as Jacob did on the R&D side. I'm quite happy with the way Steve, our CTO, and the R&D group are pushing a disciplined execution of R&D and the portfolio. At the same time, we're also very disciplined about the money we spend and about how we view OpEx moving ahead. I believe that's the outcome you're seeing. What truly pleases me is that I keep seeing better productivity within the R&D organizations as well. I'm enthusiastic about what sits in our portfolio and what will emerge across the next few years. A portion of that we've discussed. A great deal we haven't actually disclosed so far. Far more to come.

Ankur Dhingra

executive
#31

Yes, thank you, Jacob. Regarding your second question, Kyle. Alright. When it comes to the clinical acceleration over the year, consider it from two angles. We've discussed how many X units have been placed, with over 50% of Xs going into clinical settings across the past several quarters, and a substantial number placed in the most recent quarter. We mentioned that validating Xs in the clinical context takes somewhat more time compared to the research setting. What we think we're witnessing the impact of is many of our large customers launching and securing approval for multiple new tests, including in early detection, certainly in therapy selection, as well as in MRD, and in genetic disease. If you simply tally up the tests approved within just the last two, three quarters, you'll notice the considerable new activity being introduced. Many of these larger, highly intensive tests have been made possible on X, considering the sequencing intensities these new tests demand. We believe the clinical market is gaining momentum, and there is durability to this momentum moving forward too. The eventual growth rates themselves will unfold the way they will unfold. There's a lot of solid fundamental momentum accumulating in that business. Yes, and one more reminder, we did many X placements in Q4 and Q1 of 2025 and Q4 of 2024; that is now bearing out. You can observe that a large portion of those went into the clinical space, and that's where you begin to see volume originating from these placements as well.

Jack Meehan

analyst
#32

Good afternoon, everybody. Hi there. You've shared quite a few really useful remarks regarding how you're thinking about the framing for 2026. Previously, you mentioned aiming for EPS growth in the double digits. With the building blocks you've described to us, I'm just wondering how confident you are that you'll be able to achieve that in the coming year. Thanks.

Jacob Thaysen

executive
#33

Hey, Jack, great to hear from you. Yes, we keep going. Yeah, as I also said during the call, we keep going — naturally, we weren't giving guidance back when we held our investor setup last summer. As far as I remember, we weren't offering much detail regarding EPS; the focus was more on operating margin, where we stated we'd be moving from 500 basis points to 26%. Along with that, naturally, comes robust EPS growth. We're confident that we can keep growing EPS within that range you just mentioned as well. That said, it's still too early for us to provide specific guidance for the next year, but. We think we can keep doing so. I believe we've demonstrated quite clearly, through the very challenging conditions we've faced both in 2024 and here in 2025, that we've grown the EPS. Our goal is to keep doing so at that same level. Ankur?

Ankur Dhingra

executive
#34

Okay, thank you, Jacob. And Jack, indeed, there remain multiple levers we keep pursuing when it comes to expanding earnings overall. Obviously, bringing the OpEx cost structure to a point where operating leverage is significantly stronger mattered a great deal, and our sense is that we are nearing it. Maintaining rigor around that spending is one key piece; we are still working through a number of the programs described previously. How some of those turn out has not yet shown up in the P&L. There has been discussion of establishing our core centers of excellence in Singapore. There has been discussion of centers of excellence in India. There has been discussion of ongoing efforts on the gross margin for our instruments. All of these are levers we keep pulling, and there is still more value to be captured. Beyond that, as growth comes back and with an improved cost structure, operating leverage ought to be better as well; put simply, yes, our aim is to keep expanding earnings moving forward. Naturally, we will discuss the details for 2026 once we reach the guide.

Dan Brennan

analyst
#35

Oh, excellent. Dan Brennan here. How's it going? Thank you, fellas. Nice work on the quarter. Perhaps just a few. I realize some questions have already come up regarding the X transition, but that 900 basis points of quarter-over-quarter volume growth on the X, going from 55% to 64%, might we witness another 900 basis points in 4Q? What's our thinking around reaching that research-type level for the X, which sits at 90%? How long do you figure that will require? On the research side, could you unpack a bit what you're genuinely observing from your U.S. academic and government customers? How have those moved year to date in the third quarter? Should we end up with a flat budget or even a CR, do you believe that would suffice to produce a decent uptick in spending, or what are you picking up from customers regarding what would let them spend more, the research customers? Thanks.

Jacob Thaysen

executive
#36

Yeah, Dan, appreciate that. At the prior earnings call, I believe we had plenty of discussions with all of you concerning why the transition was decelerating, and now we're discussing why it's speeding up. First and foremost, what matters most is that revenue sped up alongside the faster conversion. We're quite happy about that, and we keep seeing that this trend will persist. I'll urge caution and warn against over-reading the speeding up and slowing down from quarter to quarter. The trend is the thing we should focus on. Where we stand a quarter from now, we'll take that and evaluate it. It's a single quarter; it's premature to determine whether it's how much we're accelerating, whether that's a fresh line we ought to pursue. On the whole, I'm quite encouraged by where we are. Even more importantly, I'm encouraged that we keep growing through a faster conversion. If we examine the academic setting, as I said earlier, we're glad to observe that the grants are flowing. I believe from this point forward, it's more about achieving predictability in the grant flow and the predictability that researchers can genuinely anticipate receiving future grants as well. They aren't basing their spending plans on a single grant. They're spending based on what's anticipated to arrive across the coming few quarters. I think that's the next — this was a wonderful checkmark that we now observe NIH spending. The following checkmark is, naturally, we need the budget passed, or at minimum a CR. Lastly, naturally, we need to see grants flowing on a regular basis. I think those are the steps we must pass through. How much time will that require? I don't know precisely, but it's certainly going to extend into 2026.

Subbu Nambi

analyst
#37

Hi everyone, thanks for giving me the chance to ask. I've got two short items to start. First off, Ankur, my read is that you're looking for some sequential improvement in Q4 instrument revenue excluding China, reaching $125 million. Am I understanding that correctly? Even so, it would represent a decline versus a year ago, though it's a solid move up sequentially. What's baked into your thinking about budget flush compared with what's typical historically? Second, building on what Kathleen asked, should we frame research customers as largely finished with the X transition? My reason for asking is that, in contrast to clinical — and you handled that well in the slides — I'd expect that once past the transition, growth would resume at a faster pace. Is that accurate?

Jacob Thaysen

executive
#38

Subbu, let me take the broader piece first. A particularly robust Q4 for instrument placements strikes me as entirely ordinary. That's how we typically view it. I wouldn't call it a budget flush; it's simply very typical in Q4. We observed that a year ago, and in prior years as well. Q4 tends to be the strongest. This isn't specific to Illumina. As far as I'm aware, it's a pattern across the life science tools sector. We're anticipating the same for Q4, yet we aren't factoring in any particular form of budget flush. Ankur?

Ankur Dhingra

executive
#39

Yes. Hi, Subbu. That's a fair question. The Q4 instruments were covered by Jacob. I definitely expect an improvement there, and our forecast builds one in. It won't match the 91 placements from Q4 of last year. Our forecast doesn't presume that, though it would be a pleasant upside for the total if it occurred. Regarding the research market going forward, your understanding is correct: most volumes there have shifted to X, which means once those markets start growing again, or even in a flat environment, the pricing drag itself ought to begin fading, producing stronger revenue results or revenue growth results. We're also happy about the multi-omics lineup being introduced. We believe our position is very strong for when those markets come back too. Yep, you're thinking about it correctly.

Conor McNamara

executive
#40

We appreciate everyone being with us on this call. A recording of today's session can be found in the investor portion of our site. That brings our call to an end. We hope to see all of you at events in the near future.

Operator

operator
#41

That wraps up the call for today. We appreciate everyone joining us. At this point, you're free to hang up, and we hope the rest of your day goes well.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.